We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mast Group Appointed European Distributor of Kanto Tests

By Labmedica staff writers
Posted on 14 Nov 2006
The Kanto Chemical Company (Tokyo, Japan) has appointed Mast Group Ltd. More...
(Merseyside, UK) as its authorized representative and exclusive European distributor for a range of tests for extended-spectrum beta-lactamase (ESbL) detection.

The Cica Beta products of Kanto incorporate the use of a novel chromogenic compound to differentiate between the various beta lactamase enzymes and permit confirmation of an organism as an ESbL, metallo-beta lactamase (MBL), or AmpC-type lactamase producer. Separate kits are available for each type of beta lactamase enzyme and each kit is color coded for simple identification. The kits can be used individually or in combination for comprehensive enzyme profiling.

Lactamase-producing strains of bacteria are more resistant to antibiotics and cause infections that are difficult to treat. In many instances, only two oral antibiotics and a very limited group of intravenous antibiotics are effective.

Suspect bacterial colonies are streaked onto each strip and identification is made by a clear color change from yellow to red. Results are available within 15 minutes, permitting rapid and accurate identification. The Cica Beta tests supplement the existing range of Mast's identification and antibiotic sensitivity products.

The Cica Beta kits rapidly detect enzyme production in Gram-negative isolates from patients with severe infection. ESbL production by a total of 304 strains of Klebsiella spp., Escherichia coli, and Proteus mirabilis was tested by a Cica Beta kit as well as the phenotypic confirmatory disk test (using cefotaxime and ceftazidime, with and without clavulanate). The kit showed 95.5% and 98.1% sensitivity and specificity, respectively, as compared to the disk test, and thus proved to be an appropriate tool for the rapid detection of ESbL.



Related Links:
Kanto Chemical
Mast Group

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.